<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607918</url>
  </required_header>
  <id_info>
    <org_study_id>201110019MD</org_study_id>
    <nct_id>NCT01607918</nct_id>
  </id_info>
  <brief_title>Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy</brief_title>
  <acronym>THC</acronym>
  <official_title>Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to compare the eradication rates of sequential therapy for 10 days
      versus triple therapy for 14 days
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate according to Intention to treat (ITT) and per-protocol (PP) analysis</measure>
    <time_frame>6 weeks</time_frame>
    <description>C13-UBT will be used to assess the existence of H. pylori</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects</measure>
    <time_frame>during eradication therapy</time_frame>
    <description>to assess the adverse effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Eradication Rates of the Two Regimens</condition>
  <arm_group>
    <arm_group_label>Sequential therapy 10 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple therapy 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triple therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)</intervention_name>
    <description>D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid</description>
    <arm_group_label>Sequential therapy 10 days</arm_group_label>
    <other_name>Takepron</other_name>
    <other_name>Amoxicillin</other_name>
    <other_name>Klaricid</other_name>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D1-D14: (lansoprazole + clarithromycin + amoxicillin)</intervention_name>
    <description>D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid</description>
    <arm_group_label>Triple therapy 14 days</arm_group_label>
    <other_name>Takepron</other_name>
    <other_name>Klaricid</other_name>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are aged greater than 20 years who have H. pylori infection without prior
             eradication therapy and are willing to receive the sequential therapy will be eligible
             for enrollment.

          -  Written informed consents will be obtained from all patients prior to enrollment.

        Exclusion Criteria:

        Patients will be excluded from the study if any one of the following criteria is present:

          -  children and teenagers aged less than 20 years,

          -  history of gastrectomy,

          -  gastric malignancy, including adenocarcinoma and lymphoma,

          -  previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin,
             metronidazole) and prompt pump inhibitors (lansoprazole), - contraindication to
             treatment drugs,

          -  pregnant or lactating women,

          -  severe concurrent disease

          -  Patients who cannot give informed consent by himself or herself.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Ming Liou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-Shiang Wu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD</last_name>
    <phone>886-972651883</phone>
    <email>dtmed046@pchome.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei,</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Ming Liou, MD</last_name>
      <phone>886-972651883</phone>
      <email>dtmed046@pchome.com.tw</email>
    </contact>
    <investigator>
      <last_name>Jyh-Ming Liou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010 Nov;59(11):1465-70. doi: 10.1136/gut.2010.215350.</citation>
    <PMID>20947881</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <last_update_submitted>October 27, 2013</last_update_submitted>
  <last_update_submitted_qc>October 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Taiwan University Hospital</investigator_affiliation>
    <investigator_full_name>National Taiwan University Hospital</investigator_full_name>
    <investigator_title>Doctor and Principle Investigator, Department of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>H pylori, eradication</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

